Eligible patients are invited to participate in the cohort study by the treating study physicians at approximately 20 hospitals in Germany. Participation is voluntary and requires comprehensive information and written consent from the patients in their native language. Between 2025 and 2027, all individuals aged 18 or older with confirmed multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB) may be included in the prospective study. A prerequisite is treatment for MDR/RR-TB within the study period at one of the participating study centers.  

You can find more information about the study here.

As of April 27, 2026